Search Videos and More
Molecular Tripwires and Sponges Evolved in Bacterial Struggle for Survival
Dana-Farber researchers have discovered ancient bacterial defenses and anti-defenses that may persist in some form in humans today and could provide insights into new approaches to cancer research and treatment.Immunotherapy Before and After Surgery Improves Outcomes in Head and Neck Cancer
Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025
Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study
Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancerYears of Research Help Forge a New Path in Hodgkin Lymphoma Treatment
Medical advances tend to unfold slowly over many years, fueled by successive clinical studies that build upon each other and together provide the evidence needed to change patient care.Novel Genomic Screening Tool Enables Precision Reverse-Engineering of Genetic Programming in Cells
Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a novel approach to understanding how certain proteins called transcription factors determine which genetic programs will drive cell growth and maturation.FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research
FDA decision establishes cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumorsAI Learns Genomic “Language” to Advance Cancer Treatment
The human genome is a sequence of Ts, Gs, Cs, and As that is about 3 billion letters long. And, says Bradley Bernstein, MD, PhD, chair of Dana-Farber’s Department of Cancer Biology, “there’s no dictionary or guide for reading it.”Novel Stem Cell Therapy Safely Repairs Irreversible Corneal Damage in Clinical Trial
An expanded phase clinical trial that tested a groundbreaking, experimental stem cell treatment for blinding cornea injuries found the treatment was feasible and safe in 14 patients who were treated and followed for 18 months, and there was a high proportion of complete or partial success.Early Cancer Detection Studies for High-Risk People
A blood test can now detect the presence of 50 different cancers — most of which do not have any other means of screening.Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem Meetings
Dana-Farber Cancer Institute researchers presented key research studies at the 2025 Tandem Meetings, the premier conference in hematopoietic cell transplantation (HCT) and cellular therapy.A Year of Advances in Genitourinary Cancer
Dana-Farber’s genitourinary cancer team is devoted to research that will advance patient care and improve patient’s lives. Recently, that research — all of it years in the making — has paid off with major achievements.